期刊
TEXAS HEART INSTITUTE JOURNAL
卷 42, 期 1, 页码 6-15出版社
TEXAS HEART INST
DOI: 10.14503/THIJ-14-4353
关键词
Atrial fibrillation/complications/epidemiology; decision support techniques; guidelines as topic; health status indicators; population surveillance/methods; predictive value of tests; randomized controlled trials as topic; risk assessment/methods/standards; stroke/epidemiology/prevention & control thromboembolism/epidemiology/prevention & control
资金
- Ministry of Chinese Education Innovation Team Development Plan [IRT1141]
- National Basic Research Program of China (973 Program) [2013CB531103]
- National Natural Science Foundation of China [81160023, 81370288]
- Jiangxi Science Foundation of China [20121BBG70030]
Two validated scoring systems for predicting embolic risk, CHADS(2) and CHA(2)DS(2)-VASc, contribute to optimizing antithrombotic prescription practices in patients who have atrial fibrillation. However, data about anticoagulated patients are sparse. We compared CHADS(2) and CHA(2)DS(2)-VASc, in terms of their predictive risk evaluation, in patients with atrial fibrillation who were and were not taking anticoagulants. We systematically searched the Cochrane Library, PubMed, and Embase databases for studies of the comparative diagnostic performance of CHADS(2) and CHA(2)DS(2)-VASc. We identified 12 cohort studies for meta-analysis. With regard to the occurrence of cardiovascular events individually, patients with CHA(2)DS(2)-VASc scores >= 2 have a greater risk of stroke (risk ratio [RR]=5.15; 95% confidence interval [CI], 3.85-6.88; P <0.00001) and thromboembolism (RR=5.96; 95% CI, 5.50-6.45; P <0.00001) (P-diff=0.34) than do patients with CHA(2)DS(2)-VASc scores <2, independent of anticoagulation therapy (RR=5.76; 95% CI, 5.23-6.35; P <0.00001 in anticoagulated patients; and RR=6.12; 95% CI, 5.40-6.93; P <0.00001 in patients not taking anticoagulants; P-diff=0.45). The pooled RR estimates indicate an approximate 6-fold increase in the risk of endpoint events in patients with CHA(2)DS(2)-VASc scores >= 2 (RR=5.90; 95% CI, 5.46-6.37; P <0.0001). These results clearly indicate the discriminative capacity of the CHA(2)DS(2)-VASc score for stroke, thromboembolic events, or both, independent of optimal anticoagulation. The CHA(2)DS(2)-VASc score enables the identification of patients who are at genuinely high risk and can direct the selection of appropriate therapeutic approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据